GCM
ORKA

Ghisallo Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Ghisallo Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.76M Buy
+50,000
New +$3.33M 0.09% 161

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ghisallo Capital Management's ORKA Position: Q2 2026 in Review

Ghisallo Capital Management opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 50,000 shares worth $4.76M. The stake represents 0.09% of the portfolio and ranks #161 among its holdings.

255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Ghisallo Capital Management held 50,000 shares of Oruka Therapeutics worth $4.76M as of Q2 2026.
  • Oruka Therapeutics was a new Ghisallo Capital Management position in Q2 2026.
  • Oruka Therapeutics made up 0.09% of Ghisallo Capital Management's portfolio in Q2 2026, its #161 holding.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Ghisallo Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.